CRISPR Therapeutics AG
- CRSP
- NASDAQ
- Biotechnology
- Gene Editing (CRISPR/Cas9)
- Genomic Medicines
- Cell Therapy
$49.25
Today −4.41%Quote Oct 16, 2026, 08:00 PM UTC
−14.09%over the last month
Max drawdown −16.6%From 1-month high −16.6%3 months +4.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$4.76B
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$63.17
+28.3% from here
Floor
$48.26
2.0% below price
Where the price sits
38 analysts
Analyst range, low to high
$52.00$80.00
- Price $49.25
- Resistance $50.76–$51.27
- Consensus $63.17
Analysts' average target sits about 28% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CRSPPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $10.2M
- Collaboration Revenue$10.0M98.2%
- Grant$181,0001.8%
Industry
Biotechnology
Employees
393